Association of Cortical and Subcortical beta-Amyloid With Standardized Measures of Depressive and Anxiety Symptoms in Adults Without Dementia

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00159816%3A_____%2F21%3A00075103" target="_blank" >RIV/00159816:_____/21:00075103 - isvavai.cz</a>

Výsledek na webu

<a href="https://neuro.psychiatryonline.org/doi/epdf/10.1176/appi.neuropsych.20050103" target="_blank" >https://neuro.psychiatryonline.org/doi/epdf/10.1176/appi.neuropsych.20050103</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1176/appi.neuropsych.20050103" target="_blank" >10.1176/appi.neuropsych.20050103</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Association of Cortical and Subcortical beta-Amyloid With Standardized Measures of Depressive and Anxiety Symptoms in Adults Without Dementia

Popis výsledku v původním jazyce

Objective: The purpose of this study was to test the hypothesis that subcortical beta-amyloid (A beta) deposition was associated with elevated scores on standardized measures of depressive and anxiety symptoms when compared with cortical (A beta) deposition in persons without dementia. Methods: The authors performed a cross-sectional study, derived from the population-based Mayo Clinic Study of Aging, comprising participants aged &gt;= 70 years (N=1,022; 55% males; 28% apolipoprotein E [APOE] epsilon 4 carriers; without cognitive impairment, N=842; mild cognitive impairment; N=180). To assess A beta deposition in cortical and subcortical (the amygdala, striatum, and thalamus) regions, participants underwent Pittsburgh Compound B positron emission tomography (PiB-PET) and completed the Beck Depression Inventory-II (BDI-II) and the Beck Anxiety Inventory (BAI). The investigators ran linear regression models to examine the association between PiB-PET standardized uptake value ratios (SUVRs) in the neocortex and subcortical regions and depressive and anxiety symptoms (BDI-II and BAI total scores). Models were adjusted for age, sex, education level, and APOE epsilon 4 carrier status and stratified by cognitive status (without cognitive impairment, mild cognitive impairment). Results: Cortical PiB-PET SUVRs were associated with depressive symptoms (beta=0.57 [SE=0.13], p&lt;0.001) and anxiety symptoms (beta=0.34 [SE=0.13], p=0.011). PiB-PET SUVRs in the amygdala were associated only with depressive symptoms (beta=0.80 [SE=0.26], p=0.002). PiB-PET SUVRs in the striatum and thalamus were associated with depressive symptoms (striatum: beta=0.69 [SE=0.18], p&lt;0.001; thalamus: beta=0.61 [SE=0.24], p=0.011) and anxiety symptoms (striatum: beta=0.56 [SE= 0.18], p=0.002; thalamus: beta = 0.65 [SE=0.24], p=0.008). In the mild cognitive impairment subsample, A beta deposition, regardless of neuroanatomic location, was associated with depressive symptoms but not anxiety symptoms. Conclusions: Elevated amyloid deposition in cortical and subcortical brain regions was associated with higher depressive and anxiety symptoms, although these findings did not significantly differ by cortical versus subcortical A beta deposition. This cross-sectional observation needs to be confirmed by a longitudinal study.

Název v anglickém jazyce

Association of Cortical and Subcortical beta-Amyloid With Standardized Measures of Depressive and Anxiety Symptoms in Adults Without Dementia

Popis výsledku anglicky

Objective: The purpose of this study was to test the hypothesis that subcortical beta-amyloid (A beta) deposition was associated with elevated scores on standardized measures of depressive and anxiety symptoms when compared with cortical (A beta) deposition in persons without dementia. Methods: The authors performed a cross-sectional study, derived from the population-based Mayo Clinic Study of Aging, comprising participants aged &gt;= 70 years (N=1,022; 55% males; 28% apolipoprotein E [APOE] epsilon 4 carriers; without cognitive impairment, N=842; mild cognitive impairment; N=180). To assess A beta deposition in cortical and subcortical (the amygdala, striatum, and thalamus) regions, participants underwent Pittsburgh Compound B positron emission tomography (PiB-PET) and completed the Beck Depression Inventory-II (BDI-II) and the Beck Anxiety Inventory (BAI). The investigators ran linear regression models to examine the association between PiB-PET standardized uptake value ratios (SUVRs) in the neocortex and subcortical regions and depressive and anxiety symptoms (BDI-II and BAI total scores). Models were adjusted for age, sex, education level, and APOE epsilon 4 carrier status and stratified by cognitive status (without cognitive impairment, mild cognitive impairment). Results: Cortical PiB-PET SUVRs were associated with depressive symptoms (beta=0.57 [SE=0.13], p&lt;0.001) and anxiety symptoms (beta=0.34 [SE=0.13], p=0.011). PiB-PET SUVRs in the amygdala were associated only with depressive symptoms (beta=0.80 [SE=0.26], p=0.002). PiB-PET SUVRs in the striatum and thalamus were associated with depressive symptoms (striatum: beta=0.69 [SE=0.18], p&lt;0.001; thalamus: beta=0.61 [SE=0.24], p=0.011) and anxiety symptoms (striatum: beta=0.56 [SE= 0.18], p=0.002; thalamus: beta = 0.65 [SE=0.24], p=0.008). In the mild cognitive impairment subsample, A beta deposition, regardless of neuroanatomic location, was associated with depressive symptoms but not anxiety symptoms. Conclusions: Elevated amyloid deposition in cortical and subcortical brain regions was associated with higher depressive and anxiety symptoms, although these findings did not significantly differ by cortical versus subcortical A beta deposition. This cross-sectional observation needs to be confirmed by a longitudinal study.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30210 - Clinical neurology

Projekt

<a href="/cs/project/LQ1605" target="_blank" >LQ1605: Translační medicína</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2021

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of Neuropsychiatry and Clinical Neurosciences

ISSN

0895-0172

e-ISSN

—

Svazek periodika

33

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

8

Strana od-do

64-71

Kód UT WoS článku

000610193200008

EID výsledku v databázi Scopus

—